Drug prices are soaring in 2019

Despite a major push from the Trump administration over the last few years to lower prescription drug costs, more than 3,400 drugs have seen price hikes during the first half of the year, according to a recent report.

The number of drugs with price hikes is 17% higher than the prior year, with the average price increase of 10.5%––5 times the rate of inflation, according to the analysis, conducted by Rx Savings Solutions and reported by CBS News. During the same six-month period in 2018, about 2,900 drugs had price hikes.

Amazingly, about 41 drugs have increased prices by more than 100%, CBS reported. For example, the cost of Prozac, an antidepressant, jumped a whopping 879%. The price of a topical steroid rose 381%, while a pain reliever jumped 326% and an ADHD treatment rose 118%, according to the report.

The report comes at a time when the Trump administration has been vocal about bringing down drug prices. Recently, HHS finalized a rule to mandate drugmakers to publish the list prices of prescription drugs in TV advertisements.

The findings also come as the price of insulin has sky-rocketed over the last several years, leading Eli Lilly to manufacturer a half-priced version of its insulin medication and lawmakers to question drugmakers about the price hikes.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.